QLT Announces Resignation of Vicente Anido, Jr. as Director
11 Novembro 2013 - 10:00AM
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today
announced that Vicente Anido, Jr. has resigned from the Board of
Directors of the Company, effective immediately.
"We thank Vince for his exemplary Board service on behalf of our
stakeholders," said Jason M. Aryeh, Chairman of the Board. "Vince's
insight and ophthalmological experience have been invaluable to
QLT. We wish Vince continued success as he embarks on his exciting
new endeavor as Chairman and CEO of newly public Aerie
Pharmaceuticals, Inc."
About QLT
QLT is a biotechnology company dedicated to the development and
commercialization of innovative ocular products that address the
unmet medical needs of patients and clinicians worldwide. We are
focused on developing our synthetic retinoid program for the
treatment of inherited retinal diseases.
QLT is based in Vancouver, Canada and the Company is publicly
traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange
(symbol: QLT). For more information about the Company's products
and developments, please visit our web site at www.qltinc.com.
Certain statements in this press release constitute
"forward-looking statements" of QLT within the meaning of the
Private Securities Litigation Reform Act of 1995 and constitute
"forward-looking information" within the meaning of applicable
Canadian securities laws. Forward-looking statements include,
but are not limited to: statements which contain language such as:
"assuming," "prospects," "goal," "future" "projects," "potential,"
"could," "believes," "expects"; "hopes" and "outlook."
Forward-looking statements are predictions only which involve known
and unknown risks, uncertainties and other factors that may cause
actual results to be materially different from those expressed in
such statements. Many such risks, uncertainties and other factors
are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the risks,
uncertainties and other factors following: the effect that QLT's
announcements and actions will have on the market price of our
securities; our development plans, timing and results of the
clinical development of our synthetic retinoid program; assumptions
related to continued enrollment trends, efforts and success, and
the associated costs of our synthetic retinoid program; outcomes
for our clinical trials may not be favorable or may be less
favorable than interim/preliminary results and/or previous trials;
varying interpretations of data produced by one or more of our
clinical trials; the timing, expense and uncertainty associated
with the regulatory approval process for products to advance
through development stages; risks and uncertainties associated with
the safety and effectiveness of our synthetic retinoid program;
risks and uncertainties related to the scope, validity, and
enforceability of our intellectual property rights and the impact
of patents and other intellectual property of third parties; the
Company's future operating results, which are uncertain and likely
to fluctuate; currency fluctuations; and general economic
conditions and other factors described in detail in QLT's Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q and other
filings with the U.S. Securities and Exchange Commission and
Canadian securities regulatory authorities. Forward-looking
statements are based on the current expectations of QLT and QLT
does not assume any obligation to update such information to
reflect later events or developments except as required by
law.
CONTACT: QLT Inc. Contacts:
Investor & Media Relations
Andrea Rabney or David Pitts
Argot Partners
212-600-1902
andrea@argotpartners.com
david@argotpartners.com
Quantshares U.S. Market Neutral Quality Fund Etf (AMEX:QLT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Quantshares U.S. Market Neutral Quality Fund Etf (AMEX:QLT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024